Compare OLLI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLLI | ABCL |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 2015 | 2020 |
| Metric | OLLI | ABCL |
|---|---|---|
| Price | $87.64 | $11.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $101.60 | $16.82 |
| AVG Volume (30 Days) | 1.6M | ★ 4.6M |
| Earning Date | 12-08-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.43 | 10.91 |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $2,649,198,000.00 | $75,128,000.00 |
| Revenue This Year | $10.78 | N/A |
| Revenue Next Year | $11.15 | $7.12 |
| P/E Ratio | $39.68 | ★ N/A |
| Revenue Growth | 16.62 | ★ 160.56 |
| 52 Week Low | $60.29 | $2.75 |
| 52 Week High | $130.40 | $14.98 |
| Indicator | OLLI | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 52.58 | 46.26 |
| Support Level | $71.95 | $11.78 |
| Resistance Level | $89.12 | $12.88 |
| Average True Range (ATR) | 3.23 | 0.83 |
| MACD | -0.34 | -0.22 |
| Stochastic Oscillator | 38.29 | 21.30 |
Ollie's Bargain Outlet Holdings Inc is a retailer of closeout merchandise and excess inventory. The company sells name-brand household items that consumers use every day at prices heavily discounted compared with traditional retailers. It offers customers a broad selection of brand-name products, including housewares, bed and bath, food, floor coverings, health and beauty aids, books and stationery, toys, and electronics. The company operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun, engaging treasure-hunt shopping experience, a compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.